These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 22580742)
21. Parkinson's disease in the nuclear age of neuroinflammation. Nolan YM; Sullivan AM; Toulouse A Trends Mol Med; 2013 Mar; 19(3):187-96. PubMed ID: 23318001 [TBL] [Abstract][Full Text] [Related]
22. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease. Rosa AI; Duarte-Silva S; Silva-Fernandes A; Nunes MJ; Carvalho AN; Rodrigues E; Gama MJ; Rodrigues CMP; Maciel P; Castro-Caldas M Mol Neurobiol; 2018 Dec; 55(12):9139-9155. PubMed ID: 29651747 [TBL] [Abstract][Full Text] [Related]
23. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system. Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811 [TBL] [Abstract][Full Text] [Related]
25. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497 [TBL] [Abstract][Full Text] [Related]
26. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinson's disease. McCoy MK; Ruhn KA; Blesch A; Tansey MG Adv Exp Med Biol; 2011; 691():539-40. PubMed ID: 21153359 [No Abstract] [Full Text] [Related]
28. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520 [TBL] [Abstract][Full Text] [Related]
29. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Collins LM; Toulouse A; Connor TJ; Nolan YM Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232 [TBL] [Abstract][Full Text] [Related]
30. Dopamine receptor agonists and sleep disturbances in Parkinson's disease. Chaudhuri KR; Logishetty K Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S101-4. PubMed ID: 20123546 [TBL] [Abstract][Full Text] [Related]
31. Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self-perpetuating crosstalk? Vairetti M; Ferrigno A; Rizzo V; Ambrosi G; Bianchi A; Richelmi P; Blandini F; Armentero MT Biochim Biophys Acta; 2012 Feb; 1822(2):176-84. PubMed ID: 22119596 [TBL] [Abstract][Full Text] [Related]
32. Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs. Bassani TB; Vital MA; Rauh LK Arq Neuropsiquiatr; 2015 Jul; 73(7):616-23. PubMed ID: 26200058 [TBL] [Abstract][Full Text] [Related]